Tag: carcinoid treatments

Lu 177

One Step Closer in the US to Peptide Receptor Radionuclide Therapy, PRRT, for Neuroendocrine Cancers

May 3, 2016

The clock is ticking!! With Advanced Accelerator Applications’ completed New Drug Application (NDA) submission of Lutathera to the U.S. Food and Drug Administration last week, a decision from the FDA is expected by early 2017.  Additionally, an Expanded

READ MORE
Big Apple NETs 0

December Luncheon with the Experts in New York City for the Carcinoid and Neuroendocrine Tumor Community

November 6, 2015

Carcinoid and neuroendocrine tumor (NET) patients have a unique opportunity to hear from three medical experts during Lunch with the Experts in New York City on Sunday, December 6, 2015. This special program was initiated and is sponsored by the Big Apple

READ MORE
edda gomez panzani md

In Memoriam: Edda Gomez-Panzani, MD

July 9, 2015

It is with deep sorrow that we learned of the passing of Edda Gomez-Panzani, MD on June 30, 2015. The NorCal CarciNET Community shared a tribute to Edda who “was instrumental in gaining FDA approval for Somatuline (lanreotide) for NETs patients …

READ MORE
michael farris golden rule

DENIED: Michael Farris’ Journey with Insurance for Neuroendocrine Cancer Treatment

June 8, 2015

The good news is the very positive result at the end – but the road to getting insurance coverage for Michael Farris’ participation in the PRRT (peptide receptor radionuclide therapy) clinical trial at Excel Diagnostics in Houston, Texas, was fraught…

READ MORE
suzi garber 2

Zebra Talk — A Handbook for Newly Diagnosed Carcinoid & Neuroendocrine Tumor Patients and Their Primary Care Physicians

June 11, 2014

There’s a terrific new resource for carcinoid and neuroendocrine tumor patients and their primary care physicians entitled Zebra Talk. According to Suzi Garber of Bucks County, Pennsylvania, editor, the handbook “is intended as a reference for those…

READ MORE
luncheon with the experts nyc may 2014

Luncheon with the Experts in New York City — Carcinoid and Neuroendocrine Tumor Patients Are Invited!

April 13, 2014

 

The Big Apple Noids support group invites you to join fellow carcinoid and neuroendocrine tumor (NET) patients and three medical experts for lunch on Sunday, May 4 from 12:30 to 3:30 pm in a private dining room at Dorrian’s restaurant in Manhattan…

READ MORE
sandostatin celebrating 25 years of commitment

Novartis Offers New Sandostatin LAR Depot Co-Pay Assistance Program

March 31, 2014

A new co-pay assistance program for carcinoid syndrome patients taking Sandostatin® LAR Depot has been established by Novartis Pharmaceuticals Corporation, effective February 2014.

With the Sandostatin® LAR Depot Co-Pay Assistance Program, eligible…

READ MORE
hope in sand

Remembering Dr. Martin Luther King and Sharing the Carcinoid Cancer Foundation’s Dream

August 28, 2013

Fifty years ago today, August 28, 1963, the Rev. Dr. Martin Luther King gave his historic speech, “I Have a Dream.”  That enormously powerful speech, http://youtu.be/smEqnnklfYs, still resonates with people decades later. As we listened to Dr. King’s…

READ MORE
notch 1 signaling in nets chen kunnimalaiyaan

Treating Neuroendocrine Tumors: New Patent Awarded

December 31, 2012

Herbert Chen, MD, and Muthusamy Kunnimalaiyaan, Ph.D., of the University of Wisconsin School of Medicine and Public Health in Madison, have received a patent (8,338,482) for a “Modulating Notch1 Signaling Pathway for Treating Neuroendocrine

READ MORE
ebrahim delpassand md

First U.S. Center to Enroll Patients in International, Multicenter Clinical Trial of Lu-177 Octreotate

November 20, 2012

Excel Diagnostics and Nuclear Oncology Center in Houston, Texas, is the first center in the United States to start recruiting patients in a multicenter randomized clinical trial of Lu-177 Octreotate in patients with progressive midgut carcinoid. …

READ MORE